In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. 1997

M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
Department of Geriatric Medicine, Osaka University Medical School, Japan.

Although antisense strategy has been at the center of interest in gene therapy, little is known about application of this strategy to cardiac diseases because of the lack of a suitable delivery method into the heart. Therefore, we compared the transfection efficiency of antisense oligodeoxynucleotides (ODN) using HVJ-liposome method and direct transfer in in vivo transfer into heart. To investigate the cellular fate and localization of ODN, transfer of "naked" FITC-labeled antisense ODN or ODN enwrapped in HVJ-liposome complex were examined. Following in vivo transfer using direct injection as well as in vitro transfer, fluorescence rapidly disappeared within 1 day, whereas transfer by HVJ-liposome method resulted in sustained fluorescence localized in the nucleus for at least 1 week. Measurement of fluorescence also demonstrated a significantly higher level in myocardium transfected by HVJ-liposome method than direct transfer. The present study demonstrated that HVJ-liposome method is more efficacious for ODN delivery by prolongation of half-life of ODN, suggesting its usefulness for gene therapy in cardiac diseases.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018108 Respirovirus A genus of the family PARAMYXOVIRIDAE (subfamily PARAMYXOVIRINAE) where all the virions have both HEMAGGLUTININ and NEURAMINIDASE activities and encode a non-structural C protein. SENDAI VIRUS is the type species. Respiroviruses

Related Publications

M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
July 1997, Journal of cardiovascular pharmacology and therapeutics,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
February 2000, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
December 1998, Journal of hepatology,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
January 1998, Experimental nephrology,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
April 1999, Current eye research,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
November 1995, Circulation,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
January 1999, Somatic cell and molecular genetics,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
December 2005, Transplantation,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
May 2008, Brain & development,
M Aoki, and R Morishita, and J Higaki, and A Moriguchi, and I Kida, and S Hayashi, and H Matsushita, and Y Kaneda, and T Ogihara
May 1999, Journal of hepatology,
Copied contents to your clipboard!